Navigation Links
Pharmasset Reports Financial Results for Quarter Ended June 30, 2008
Date:8/14/2008

p>

--------------------------

ASSETS

CURRENT ASSETS:

Cash and cash equivalents $51,048,837 $68,745,694

Short-term investments 987,126 1,252,113

Amounts due under collaborative agreements 1,863,843 919,110

Prepaid expenses and other assets 1,189,002 783,311

--------------------------

Total current assets 55,088,808 71,700,228

--------------------------

EQUIPMENT AND LEASEHOLD IMPROVEMENTS:

Laboratory, office furniture and equipment 3,240,023 2,462,647

Leasehold improvements 1,836,553 1,836,553

--------------------------

5,076,576 4,299,200

Less accumulated depreciation and amortization (2,185,498) (1,437,080)

--------------------------

Total equipment and leasehold

improvements, net 2,891,078 2,862,120

OTHER ASSETS 249,875 1,282,051

--------------------------

TOTAL $58,229,761 $75,844,399

==========================

LIABILITIES AND STOCKHOLDERS' EQUITY

CURRENT LIABILITIES:

Current portion of long-term debt $1,167,289 $-

Current portion of capital lease obligation 82,558 159,440

Accounts payable 1,314,299 3,281,600

Accrued expenses
'/>"/>

SOURCE Pharmasset, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Pharmasset Reports Preliminary Results of a 4-week Combination Study of R7128 for the Treatment of Chronic Hepatitis C
2. Pharmasset Announces Initiation of Combination Study of Clevudine and Viread(R) for HBV by French National Agency for Research on AIDS and Viral Hepatitis (ANRS)
3. Pharmasset Receives Notice of Allowance
4. Pharmasset Nominates PSI-7851 as a Lead Development Candidate for the Treatment of Chronic Hepatitis C
5. Pharmasset Commences Dosing R7128 Cohorts 3 and 4 for the Treatment of Chronic Hepatitis C
6. Pharmasset Presents Results of 4-Week Combination Study of R7128 for the Treatment of Chronic Hepatitis C
7. Pharmasset Reports First Fiscal Quarter 2008 Financial Results
8. Roche and Pharmasset To Present the R7128 Monotherapy Resistance Profile
9. Pharmasset Announces R7128 Achieves 85% Rapid Virologic Response in a 4-week Combination Study for the Treatment of Chronic Hepatitis C
10. Pharmasset Announces Clevudine and R7128 Presentations at HEP-DART
11. Pharmasset Commences Dosing in 28-Day Combination Study of R7128 with Pegasys(R) plus Copegus(R) for Hepatitis C
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/17/2013)... 17, 2013  Sorrento Therapeutics, Inc. (OTCBB: SRNE; ... Technology Small Business Technology Transfer Research (STTR) grant ... Infectious Diseases (NIAID), a division of the National ... novel human antibody therapeutics to combat Staphylococcus ... infections, including methicillin-resistant S. aureus (MRSA), ...
(Date:5/17/2013)... 17, 2013  Technology advances have had a ... with a constantly evolving communication environment, companies need ... communicating with internal executives. It is challenging, however, ... tactics and tools that are part of today,s ... study, Best Practices, LLC explores the various internal ...
(Date:5/17/2013)... Biotechnology Inc. ("Sony") today announced the launch of the new ... Sony will also be exhibiting its newly rebranded reagent portfolio. ... EC800 flow cytometer, and new SP6800 Spectral Analyzer will be ... held at the San Diego Convention ... May 20 - 22.  The 8-well strip ...
Breaking Medicine Technology:Sorrento Therapeutics, Inc. announces its approach to developing human antibody therapeutics against MRSA receives continued support from the National Institute of Allergy and Infectious Diseases 2Sorrento Therapeutics, Inc. announces its approach to developing human antibody therapeutics against MRSA receives continued support from the National Institute of Allergy and Infectious Diseases 3Sorrento Therapeutics, Inc. announces its approach to developing human antibody therapeutics against MRSA receives continued support from the National Institute of Allergy and Infectious Diseases 4Internal Communication Strategies and Tactics that Resonate with Key Stakeholders and Drive Organizational Effectiveness 2Sony Delivers New Technology for Science to CYTO 2013 2
... For years, homecare equipment providers have cited the many ramifications ... of power wheelchairs for beneficiaries.  It is the root cause of ... and it restricts access to power wheelchairs for patients.  But rarely, ... , , ...
... July 16 Human erythropoietin (EPO) is a potent ... spinal cord injury, and Parkinson,s disease. However, EPO drug development ... the blood-brain barrier (BBB). In acute stroke or brain injury, ... insult when neuroprotection is still possible. Therefore, large molecule biopharmaceuticals ...
Cached Medicine Technology:Physician Outraged by Medicare Power Wheelchair Documentation Policy 2Physician Outraged by Medicare Power Wheelchair Documentation Policy 3Physician Outraged by Medicare Power Wheelchair Documentation Policy 4ArmaGen® Re-engineers Erythropoietin for Brain Penetration 2
(Date:5/20/2013)... Minn. Patients with inflammatory bowel disease (IBD) are ... cancer, report researchers at Mayo Clinic. Researchers found that ... for the disease. The findings were presented at the ... More than 1.5 million Americans have Crohn,s disease or ... bowel disease. Both conditions inflame the lining of the ...
(Date:5/20/2013)... ParentMagic, the creator of the best selling parenting book ... in the month of May 2013. In addition to 1-2-3 ... and anyone interested in learning more about ADD and ADHD. ... materials, ParentMagic offers DVDs and Audio of the 1-2-3 Magic ... and teacher editions. , Parents who have children in several ...
(Date:5/20/2013)... May 20, 2013 The latest initiative ... assist students who wish to take admission to leading ... will start from June 1, to guide students in ... for leading management colleges. , IMP has been ... IGNOU and other open universities for completing assignments and ...
(Date:5/20/2013)... B. E. Smith, the only ... providers, has been retained to lead a national ... Hospital in Oswego, N.Y. The top executive search ... has recently placed more than 900 healthcare executives ... 164-bed, Joint Commission-accredited, acute care facility offering a ...
(Date:5/20/2013)... 2013 When developing diet plans, many ... are taken into consideration to help patients discover the ... determined that there is a clear connection between certain ... science behind these studies and others when creating their ... study exploring the effect weight gain may have on ...
Breaking Medicine News(10 mins):Health News:ParentMagic Announces May Sale, 20% Off Entire Catalog of Best Selling Books 2Health News:IGNOU MBA Project Launches Workshop for MBA Aspirants 2Health News:Oswego Hospital Retains B. E. Smith to Recruit New COO 2Health News:hCGTreatments / Diet Doc hCG Diets & Weight Loss Plans Announces New Improved hCG Diet Helping Patient’s Control Eating Impulses 2Health News:hCGTreatments / Diet Doc hCG Diets & Weight Loss Plans Announces New Improved hCG Diet Helping Patient’s Control Eating Impulses 3
... Calif, Nov. 3 BioMarin Pharmaceutical,Inc. (Nasdaq: ... Morquio Clinical,Assessment Program (MorCAP) for patients with the ... Morquio A Syndrome. MorCAP is,designed to augment available ... function and other parameters in affected patients.,BioMarin expects ...
... Services Cited as Pivotal to ... Efficiency Statewide, NASHVILLE, Tenn., Nov. 3 Emdeon, ... for the healthcare industry,has been named the electronic data ... Association (MHA). Emdeon was selected,through a competitive bidding process ...
... Va., Nov. 3 "When my father was formally,diagnosed ... book,pamphlet, and newspaper article I could get my hands ... Conversation About Alzheimer,s" (published by,AuthorHouse -- http://www.authorhouse.com ). ... I told myself that once I knew the facts, ...
... its inaugural list of the top 100, ... a leading,provider of kidney care services for those ... named in the top 100 of Modern Healthcare,s,Best ... on the list, is,the only nationwide healthcare services ...
... Nov. 3 Sabin Robbins, a,75-year old prostate ... Florida to benefit from treatment with new RapidArc(TM),radiotherapy ... Cancer Center of Boynton Beach, Florida. RapidArc, which ... ), unleashes the precision of,intensity-modulated radiation therapy (IMRT) ...
... MiddleBrook,Pharmaceuticals, Inc. (Nasdaq: MBRK ), ... novel anti-infective products, today,announced that it has ... VCG,& Associates will serve as MiddleBrook,s strategic ... pricing and reimbursement, contract,administration, national account management ...
Cached Medicine News:Health News:BioMarin Announces Initiation of Clinical Assessment Program for Morquio A Syndrome 2Health News:BioMarin Announces Initiation of Clinical Assessment Program for Morquio A Syndrome 3Health News:BioMarin Announces Initiation of Clinical Assessment Program for Morquio A Syndrome 4Health News:Emdeon Selected by the Maryland Hospital Association to Power the Maryland Transaction Data Interchange 2Health News:'A Conversation About Alzheimer's': Woman Shares Story of Love, Hope, Loss and Survival in New Book About Alzheimer's Disease 2Health News:Modern Healthcare Names DaVita One of the Best Places to Work 2Health News:Cancer Patients in Southeastern Florida Now Benefiting From RapidArc(TM) Radiotherapy Treatments 2Health News:Cancer Patients in Southeastern Florida Now Benefiting From RapidArc(TM) Radiotherapy Treatments 3Health News:MiddleBrook Pharmaceuticals Retains National Account Firm VCG & Associates 2Health News:MiddleBrook Pharmaceuticals Retains National Account Firm VCG & Associates 3
... is a variation of Volk's ... 20mm provides 1.44x magnification and ... element. The lens is designed ... sits under the patients eyelid ...
... Direct Laser Lens affords the practitioner a ... of the eye. Utilizing a unique solid ... glass LaserWindow™ exterior, this special optical design ... profile fundus lenses. Available in Volk's exclusive ...
... The Volk PDT Laser Lens has been ... spot size onto the retina during photodynamic ... the optimum combination of field (137° FOV) ... carefully chosen after consultation with Dr. Peter ...
... diopter contact lens has been specifically designed ... lamp when traditional non-contact slit lamp lenses ... Plus delivers an outstanding 137° dynamic field ... pupils as small as 3mm.Evaluated by Harvey ...
Medicine Products: